• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用表达I型人T细胞白血病病毒包膜基因的重组痘苗病毒免疫的食蟹猴中保护性免疫的长期持续存在。

Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.

作者信息

Ibuki K, Funahashi S I, Yamamoto H, Nakamura M, Igarashi T, Miura T, Ido E, Hayami M, Shida H

机构信息

Institute for Virus Research, Kyoto University, Japan.

出版信息

J Gen Virol. 1997 Jan;78 ( Pt 1):147-52. doi: 10.1099/0022-1317-78-1-147.

DOI:10.1099/0022-1317-78-1-147
PMID:9010298
Abstract

To develop effective vaccines against infection with human T cell leukaemia virus type I (HTLV-I), we constructed a recombinant vaccinia virus (WR-SFB5env) synthesizing the HTLV-I envelope (Env) gp46 protein under the control of a strong promoter, termed the ATI hybrid promoter. WR-SFB5env expressed a large quantity of gp46. In cynomolgus monkeys (Macaca fascicularis) immunized with WR-SFB5env, anti-HTLV-I Env antibody, including neutralizing antibody, was induced and remained at a high level until 136 weeks (2-6 years) post-infection (p.i.). These immunized monkeys had HTLV-I Env-specific cytotoxic T lymphocyte activity. At 136 weeks p.i., the immunized monkeys were challenged with an HTLV-I-producing cynomolgus T lymphocyte cell line. Neither HTLV-I antigen nor HTLV-I proviruses were detected in peripheral blood mononuclear cells, lymph nodes or spleens of the WR-SFB5env-immunized monkeys, in contrast to non-immunized control monkeys. These results indicate that a single immunization with WR-SFB5env induced prolonged humoral and cellular immune responses to HTLV-I and protected the monkeys against virus challenge.

摘要

为研发针对人类I型T细胞白血病病毒(HTLV-I)感染的有效疫苗,我们构建了一种重组痘苗病毒(WR-SFB5env),该病毒在一个名为ATI杂交启动子的强启动子控制下合成HTLV-I包膜(Env)gp46蛋白。WR-SFB5env表达了大量的gp46。在用WR-SFB5env免疫的食蟹猴(食蟹猕猴)中,诱导产生了包括中和抗体在内的抗HTLV-I Env抗体,并且在感染后(p.i.)136周(2 - 6年)一直维持在高水平。这些免疫的猴子具有HTLV-I Env特异性细胞毒性T淋巴细胞活性。在感染后136周,用产生HTLV-I的食蟹猴T淋巴细胞系对免疫的猴子进行攻击。与未免疫的对照猴子相比,在WR-SFB5env免疫的猴子的外周血单核细胞、淋巴结或脾脏中均未检测到HTLV-I抗原或HTLV-I前病毒。这些结果表明,单次用WR-SFB5env免疫可诱导对HTLV-I的长期体液免疫和细胞免疫反应,并保护猴子免受病毒攻击。

相似文献

1
Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.用表达I型人T细胞白血病病毒包膜基因的重组痘苗病毒免疫的食蟹猴中保护性免疫的长期持续存在。
J Gen Virol. 1997 Jan;78 ( Pt 1):147-52. doi: 10.1099/0022-1317-78-1-147.
2
Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I.用携带I型人嗜T细胞病毒包膜基因的重组痘苗病毒对兔子进行接种。
Int J Cancer. 1995 Feb 8;60(4):567-70. doi: 10.1002/ijc.2910600423.
3
Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli.通过用在大肠杆菌中产生的病毒env基因产物进行免疫接种,保护食蟹猴免受I型人类T细胞白血病病毒感染。
Int J Cancer. 1987 Sep 15;40(3):403-7. doi: 10.1002/ijc.2910400320.
4
Expression and immunogenicity of the entire human T cell leukaemia virus type I envelope protein produced in a baculovirus system.杆状病毒系统中产生的整个人T细胞白血病病毒I型包膜蛋白的表达及免疫原性
J Gen Virol. 1993 Feb;74 ( Pt 2):211-22. doi: 10.1099/0022-1317-74-2-211.
5
Lymphoid organs as a major reservoir for human T-cell leukemia virus type 1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses.在实验感染的松鼠猴(松鼠猴属)中,淋巴器官作为人类1型T细胞白血病病毒的主要储存库:前病毒表达、持续性以及体液和细胞免疫反应
J Virol. 2000 May;74(10):4860-7. doi: 10.1128/jvi.74.10.4860-4867.2000.
6
Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene.含有人类嗜T淋巴细胞病毒I型(HTLV-I)包膜基因的重组腺病毒5型DNA质粒和痘苗病毒在大鼠体内的表达及免疫原性
Int J Cancer. 1997 Apr 10;71(2):300-7. doi: 10.1002/(sici)1097-0215(19970410)71:2<300::aid-ijc27>3.0.co;2-j.
7
Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).重组人1型T细胞白血病/淋巴瘤病毒NYVAC及裸DNA候选疫苗在松鼠猴(松鼠猴属)中的免疫原性和保护效力
J Virol. 2001 Jul;75(13):5939-48. doi: 10.1128/JVI.75.13.5939-5948.2001.
8
Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.1型人类嗜T淋巴细胞病毒(HTLV-I)包膜糖蛋白46(gp46)的B细胞免疫显性表位的鉴定
Cancer Lett. 1992 Sep 14;66(1):11-20. doi: 10.1016/0304-3835(92)90274-y.
9
Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene.源自表达人I型T细胞白血病病毒包膜基因的减毒株的重组痘苗病毒的效应和毒力。
J Virol. 1988 Dec;62(12):4474-80. doi: 10.1128/JVI.62.12.4474-4480.1988.
10
Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.通过肽免疫在体外和体内诱导中和人T细胞白血病病毒I型感染的抗体反应。
J Virol. 1994 Oct;68(10):6323-31. doi: 10.1128/JVI.68.10.6323-6331.1994.

引用本文的文献

1
Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies.人类1型T细胞白血病病毒:致癌潜力与疫苗开发策略
Front Cell Infect Microbiol. 2025 Aug 15;15:1587802. doi: 10.3389/fcimb.2025.1587802. eCollection 2025.
2
HTLV-1 vaccination Landscape: Current developments and challenges.人类嗜T淋巴细胞病毒1型疫苗发展概况:当前进展与挑战
Vaccine X. 2024 Jul 16;19:100525. doi: 10.1016/j.jvacx.2024.100525. eCollection 2024 Aug.
3
An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
一种人嗜T淋巴细胞病毒1型包膜mRNA疫苗在新西兰兔中具有免疫原性且有保护作用。
J Virol. 2024 Feb 20;98(2):e0162323. doi: 10.1128/jvi.01623-23. Epub 2024 Jan 9.
4
Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.人 T 细胞嗜淋巴细胞病毒 1 型(HTLV-1)候选疫苗:临床前和临床研究的系统评价。
BMC Infect Dis. 2023 May 11;23(1):320. doi: 10.1186/s12879-023-08289-7.
5
Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.预防 HTLV-1 感染疫苗的最新进展:过去 35 年的系统性综述。
Front Immunol. 2023 Feb 13;14:1073779. doi: 10.3389/fimmu.2023.1073779. eCollection 2023.
6
Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.用短期培养的自体 PBMC 进行免疫接种能有效地激活自然感染 STLV-1 的日本猕猴中受损的 CTL 反应的 STLV-1 特异性 CTL。
PLoS Pathog. 2023 Feb 2;19(2):e1011104. doi: 10.1371/journal.ppat.1011104. eCollection 2023 Feb.
7
Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines.人 T 细胞白血病病毒 1 劫持宿主免疫:对治疗性和预防性疫苗的影响。
Viruses. 2022 Sep 20;14(10):2084. doi: 10.3390/v14102084.
8
A role for an HTLV-1 vaccine?是否需要 HTLV-1 疫苗?
Front Immunol. 2022 Sep 8;13:953650. doi: 10.3389/fimmu.2022.953650. eCollection 2022.
9
The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.人类T细胞白血病病毒1型疫苗的过去、现在与未来
Front Microbiol. 2022 May 4;13:897346. doi: 10.3389/fmicb.2022.897346. eCollection 2022.
10
Animal Models Utilized in HTLV-1 Research.用于人类嗜T淋巴细胞病毒1型(HTLV-1)研究的动物模型。
Virology (Auckl). 2013 Nov 18;4:49-59. doi: 10.4137/VRT.S12140. eCollection 2013.